Toxic epidermal necrosis - Poizoni Epidermal Necrosishttps://en.wikipedia.org/wiki/Toxic_epidermal_necrolysis
Poizoni Epidermal Necrosis (Toxic epidermal necrosis) ndi mtundu wowopsa wakhungu. Zizindikiro zoyamba ndi kutentha thupi komanso ngati chimfine. Patangopita masiku angapo, khungu limayamba kuchita matuza ndi kusenda ndikupanga madera opweteka. Ndikofunikira kuti mucous nembanemba, monga pakamwa, nawonso azikhudzidwa. Zovuta zimaphatikizapo kutaya madzi m'thupi, sepsis, chibayo, ndi kulephera kwa ziwalo zingapo.

Choyambitsa chachikulu ndi mankhwala ena monga lamotrigine, carbamazepine, allopurinol, maantibayotiki a sulfonamide, ndi nevirapine. Zowopsa zimaphatikizapo HIV ndi systemic lupus erythematosus. Nthawi zambiri chithandizo chimachitikira m'chipatala monga m'chipinda chowotcha kapena muchipinda cha odwala mwakayakaya.

Machiritso
Awa ndi matenda oopsa, kotero ngati milomo yanu kapena pakamwa mwakhudzidwa kapena khungu lanu likuchita matuza, onani dokotala mwamsanga.
Mankhwala okayikitsa ayenera kusiyidwa. (mwachitsanzo, maantibayotiki, mankhwala oletsa kutupa)

☆ Muzotsatira za 2022 Stiftung Warentest zochokera ku Germany, kukhutitsidwa kwa ogula ndi ModelDerm kunali kotsika pang'ono kusiyana ndi kuyankhulana kwa telemedicine komwe kulipiridwa.
  • Kutaya khungu kwa Poizoni Epidermal Necrosis (Toxic epidermal necrosis)
  • TENS -tsiku 10
  • Necrolysis epidermalis toxica
  • Matuza oyambilira amatha kupita patsogolo mwachangu ndikuphatikiza thupi lonse m'masiku ochepa.
References Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Diagnosis and Management 34577817 
NIH
Stevens-Johnson Syndrome (SJS) ndi Toxic Epidermal Necrolysis (TEN) ndizovuta zomwe khungu limakumana ndi necrosis ndi kukhetsedwa. Pankhani ya chithandizo, cyclosporine imakhala yothandiza kwambiri kwa SJS, pamene kuphatikiza kwa intravenous immunoglobulin (IVIg) ndi corticosteroids kumagwira ntchito bwino pazochitika za SJS ndi TEN.
Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are rare diseases that are characterized by widespread epidermal necrosis and sloughing of skin. Regarding treatment, cyclosporine is the most effective therapy for the treatment of SJS, and a combination of intravenous immunoglobulin (IVIg) and corticosteroids is most effective for SJS/TEN overlap and TEN.
 Toxic Epidermal Necrolysis: A Review of Past and Present Therapeutic Approaches 36469487
Toxic epidermal necrolysis (TEN) ndizovuta kwambiri zapakhungu zomwe zimachitika chifukwa cha mankhwala ena komanso chitetezo chamthupi, zomwe zimapangitsa kuti pakhale kutuluka kwakukulu kwa khungu lakunja (epidermis) , lomwe limakhudza kuposa 30% ya thupi. TEN ili ndi chiwopsezo cha kufa chopitilira 20%, nthawi zambiri chifukwa cha matenda komanso kupuma movutikira. Kusiya mankhwala omwe amayambitsa zomwe zimachitika, kupereka chithandizo chothandizira, ndi kugwiritsa ntchito mankhwala owonjezera kungapangitse zotsatira zake. Kafukufuku waposachedwapa wasonyeza kuti mankhwala monga cyclosporine, tumor necrosis factor alpha inhibitors, ndi kuphatikiza kwa intravenous immune globulin ndi corticosteroids kungakhale kothandiza, kutengera mayesero olamulidwa mwachisawawa ndi kusanthula maphunziro angapo.
Toxic epidermal necrolysis (TEN) is a serious skin reaction caused by certain medications and immune system activity, resulting in large-scale detachment of the outer skin layer (epidermis), affecting more than 30% of the body's surface. TEN has a mortality rate of over 20%, often due to infections and breathing difficulties. Stopping the medication causing the reaction, providing supportive care, and using additional treatments can improve the outcome. Recent studies have shown that drugs like cyclosporine, tumor necrosis factor alpha inhibitors, and a combination of intravenous immune globulin and corticosteroids can be helpful, based on randomized controlled trials and analyses of multiple studies.
 Toxic Epidermal Necrolysis and Steven–Johnson Syndrome: A Comprehensive Review 32520664 
NIH
Recent Advances: There is improved understanding of pain and morbidity with regard to the type and frequency of dressing changes. More modern dressings, such as nanocrystalline, are currently favored as they may be kept in situ for longer periods. The most recent evidence on systemic agents, such as corticosteroids and cyclosporine, and novel treatments, are also discussed.